Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
12/14/2006 | US20060280722 Treatment of follicular lymphomas using inhibitors of the LT pathway |
12/14/2006 | CA2820200A1 Compositions and methods for enhancing nitric oxide delivery |
12/14/2006 | CA2654446A1 Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
12/14/2006 | CA2654440A1 Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
12/14/2006 | CA2611646A1 Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
12/14/2006 | CA2611446A1 Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea |
12/14/2006 | CA2611416A1 Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method for the production thereof |
12/14/2006 | CA2611319A1 Inhibitors of the .alpha.2.beta.1/gpia-iia integrin |
12/14/2006 | CA2611200A1 Stabilised il-21 compositions |
12/14/2006 | CA2610986A1 Agent for treating and/or preventing neuropathic pain |
12/14/2006 | CA2610976A1 Use of stefin a as a scaffold protein |
12/14/2006 | CA2610956A1 Improved treatment for anemia using a hif-alpha stabilising agent |
12/14/2006 | CA2610791A1 Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
12/14/2006 | CA2610396A1 Organic compounds |
12/14/2006 | CA2610022A1 Compositions and methods for lipo modeling |
12/14/2006 | CA2609865A1 Modulation of cholesteryl ester transfer protein (cetp) activity |
12/14/2006 | CA2609401A1 Erythropoietin receptor peptide formulations and uses |
12/14/2006 | CA2609209A1 Topical oligopeptide delivery system |
12/14/2006 | CA2609205A1 Improved human interferon molecules and their uses |
12/14/2006 | CA2585017A1 Biocides |
12/13/2006 | EP1731912A2 Peptide selection method |
12/13/2006 | EP1731609A1 Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF |
12/13/2006 | EP1731605A1 Cancer antigen peptides derived from wt1 |
12/13/2006 | EP1731602A1 Pharmaceutical composition for lowering blood sugar level |
12/13/2006 | EP1731531A2 Multiple cytokine-antibody complexes |
12/13/2006 | EP1731529A1 Calcium ion leakage inhibitors |
12/13/2006 | EP1731193A1 Electro-medical device for use with biologics |
12/13/2006 | EP1731174A2 Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond |
12/13/2006 | EP1731171A1 Preventive/remedy for respiratory diseases |
12/13/2006 | EP1731164A1 Methods for using the obese gene and its gene product to stimulate hematopoietic development |
12/13/2006 | EP1731163A2 Treatment of allergic conditions by use of IL 21 |
12/13/2006 | EP1731162A2 Apparatus, method and compositions for the treatment of cancers by ultraphoresis |
12/13/2006 | EP1731161A1 Compositions for the treatment of diseases associated with elevated sphingolipid concentrations |
12/13/2006 | EP1731160A1 Cancer metastasis inhibitory composition |
12/13/2006 | EP1731144A1 Identification of genes altered in multiple myeloma |
12/13/2006 | EP1730535A2 Hausp-mdm2 interaction and uses thereof |
12/13/2006 | EP1730528A2 Method of optimizing treatment with interferon-tau |
12/13/2006 | EP1730282A1 Glycosylation variants of ricin-like proteins |
12/13/2006 | EP1730279A2 Epha4 as therapeutic target of prc and pdaca |
12/13/2006 | EP1730270A1 Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics |
12/13/2006 | EP1730198A2 Adzymes and uses thereof |
12/13/2006 | EP1730189A2 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
12/13/2006 | EP1730188A2 Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity |
12/13/2006 | EP1730187A1 Immunosuppressive cytokine |
12/13/2006 | EP1730185A1 Cancer associated antigens |
12/13/2006 | EP1730184A2 Improved interleukin-2 muteins |
12/13/2006 | EP1730182A2 Chimeric vegf peptides |
12/13/2006 | EP1730180A1 Antifungal peptides |
12/13/2006 | EP1730179A1 Novel mannose-specific adhesins and their use |
12/13/2006 | EP1730178A2 Novel antibiotic alternatives |
12/13/2006 | EP1730176A2 Mvl, an antiviral protein from a cyanobacterium |
12/13/2006 | EP1730174A1 Peptide carrier for drug delivery |
12/13/2006 | EP1730172A1 Methods and compositions for the treatment of gastrointestinal disorders |
12/13/2006 | EP1730170A2 Method for inhibiting immune complex formation in a subjetc |
12/13/2006 | EP1730167A1 Macrocyclic peptides active against the hepatitis c virus |
12/13/2006 | EP1730166A2 Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections |
12/13/2006 | EP1730165A1 Inhibitors of hepatitis c virus ns3 protease |
12/13/2006 | EP1730142A1 Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
12/13/2006 | EP1729817A1 Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin |
12/13/2006 | EP1729810A2 Methods of reducing aggregation of il-1ra |
12/13/2006 | EP1729797A1 Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants |
12/13/2006 | EP1729796A1 Pressure sore treatment |
12/13/2006 | EP1729795A2 Albumin fusion proteins |
12/13/2006 | EP1729794A1 A pharmaceutical composition comprising an active principle and sulphobetaine |
12/13/2006 | EP1729793A1 Alk7 and myostatin inhibitors and uses thereof |
12/13/2006 | EP1729792A2 Y4 selective receptor agonists for therapeutic interventions |
12/13/2006 | EP1729791A2 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
12/13/2006 | EP1729790A1 Amphipathic glycopeptides |
12/13/2006 | EP1729788A1 Restenosis therapy using mesenchymal stem cells |
12/13/2006 | EP1729757A2 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism |
12/13/2006 | EP1729747A2 Thiol reactive agents as a therapeutic modality |
12/13/2006 | EP1729733A1 Hydrogel microspheres with improved release profile |
12/13/2006 | EP1729593A1 Cysteine protease from ginger (zingiber) as a food improver and anti-inflammatory |
12/13/2006 | EP1729570A1 Ion channel |
12/13/2006 | EP1617860A4 Biodegradable glucosaminemuramyl peptides for apoptosis modulation |
12/13/2006 | EP1551441B1 Peptides and recombinant proteins mimicking interferons |
12/13/2006 | EP1551334A4 Medical device for intra-lumenal delivery of pharmaceutical agents |
12/13/2006 | EP1515735B1 Botulinum toxins for treating priapism |
12/13/2006 | EP1482975B1 Prevention of tissue adhesion |
12/13/2006 | EP1478382B1 Method for producing a powder inhalant containing a salt of the cgrp antagonist bibn4096 |
12/13/2006 | EP1343896B1 Small acid-soluble spore protein and uses thereof |
12/13/2006 | EP1338651B1 Method of screening remedy for diabetes |
12/13/2006 | EP1313488B1 Compositions and methods for improving cardiovascular function |
12/13/2006 | EP1290201B1 Recombinant subunit proteins from porcine parvovirus produced in plants |
12/13/2006 | EP1287133B1 Regulation of human dopamine-like g protein-coupled receptor |
12/13/2006 | EP1261712B1 Proteins named fctrx and nucleic acids encoding same |
12/13/2006 | EP1206554B1 Activatable recombinant neurotoxins |
12/13/2006 | EP1179067B1 Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily |
12/13/2006 | EP1171605B1 Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof |
12/13/2006 | EP1171156B1 Isolierte inslen, die insulin-produzierende zellen enthalten, beschichtete mit heparin |
12/13/2006 | EP1147208B1 Compositions and methods for intraductal gene therapy |
12/13/2006 | EP1143989B1 Exendins for glucagon suppression |
12/13/2006 | EP1124961B1 Thrombopoietic compounds |
12/13/2006 | EP1123392B1 Prv-1 gene and the use thereof |
12/13/2006 | EP1117803B1 Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus |
12/13/2006 | EP1117795B1 Tgf-beta superfamily mutant members, including morphogenic proteins |
12/13/2006 | EP1108786B1 Novel collectin |
12/13/2006 | EP1091930B1 C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
12/13/2006 | EP1078078B1 Complex formed by a peptide and a major histocompatibility complex at the surface of phages |
12/13/2006 | EP1011704B1 Tumor necrosis factor receptor-derived peptide analogues |